Kesang Li

Title: The Innovations of Kesang Li

Introduction

Kesang Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric antigen receptors. His work focuses on advancing cancer therapies through innovative genetic modifications.

Latest Patents

Kesang Li holds a patent for "Chimeric antigen receptors targeting GPC3 and uses thereof." This patent describes a nucleic acid encoding a chimeric antigen receptor expressed on the surface of T lymphocytes. The chimeric antigen receptor comprises an extracellular binding domain, a transmembrane region, and an intracellular signaling domain. The extracellular binding domain includes a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. This innovation aims to enhance the effectiveness of genetically modified T lymphocytes in targeting cancer cells.

Career Highlights

Kesang Li is associated with Carsgen Therapeutics Limited, where he continues to push the boundaries of cancer treatment. His work has garnered attention for its potential to improve patient outcomes through targeted therapies. With 1 patent to his name, he is recognized as a key figure in his field.

Collaborations

Some of his notable coworkers include Zonghai Li and Huiping Gao, who contribute to the collaborative efforts at Carsgen Therapeutics Limited.

Conclusion

Kesang Li's innovative work in the field of chimeric antigen receptors represents a significant advancement in cancer therapy. His contributions are paving the way for new treatment options that could benefit many patients in the future.